101.55

0.54% 0.55

After Hours: 101.55

Mirum Pharmaceuticals Inc (MIRM)

Overview News Price History Option Chain Financials Why MIRM Down? Discussions Forecast

Mirum Pharmaceuticals Inc stock is traded at $101.55, with a volume of 868.71K. It is up +0.54% in the last 24 hours and down -0.62% over the past month. Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.

Previous Close:

$101.00

Open:

$100.66

24h Volume:

868.71K

Relative Volume:

0.92

Market Cap:

$6.19B

Revenue:

$521.31M

Net Income/Loss:

$-23.36M

P/E Ratio:

-212.40

EPS:

-0.4781

Net Cash Flow:

$54.87M

1W Performance:

+6.36%

1M Performance:

-0.62%

6M Performance:

+51.45%

1Y Performance:

+101.41%

1-Day Range:

$100.01

$103.36

1-Week Range:

$93.81

$104.44

52-Week Range:

$47.89

$114.99

Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile

Name

Mirum Pharmaceuticals Inc

Sector

Healthcare (1107)

Industry

Biotechnology (621)

Phone

650-667-4085

Address

989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY

Employee

418

Twitter

@mirumpharma

Next Earnings Date

2026-08-05

Latest SEC Filings

MIRM's Discussions on Twitter

Compare MIRM vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MIRM Mirum Pharmaceuticals Inc	101.55	6.16B	521.31M	-23.36M	54.87M	-0.4781
VRTX Vertex Pharmaceuticals Inc	453.17	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.73	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	878.49	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	281.90	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	156.58	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-18-26	Initiated	RBC Capital Mkts	Outperform
Sep-24-25	Initiated	TD Cowen	Buy
Aug-11-25	Resumed	Stifel	Buy
May-19-25	Resumed	H.C. Wainwright	Buy
Apr-17-24	Initiated	Stifel	Buy
Dec-18-23	Reiterated	H.C. Wainwright	Buy
Nov-20-23	Resumed	JP Morgan	Overweight
Nov-13-23	Initiated	Morgan Stanley	Overweight
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-17-23	Resumed	Evercore ISI	Outperform
Sep-20-23	Initiated	JMP Securities	Mkt Outperform
Sep-01-22	Initiated	Citigroup	Buy
Sep-20-21	Initiated	JP Morgan	Overweight
Aug-07-20	Upgrade	Raymond James	Outperform → Strong Buy
Aug-03-20	Initiated	H.C. Wainwright	Buy
Jul-31-20	Initiated	Piper Sandler	Overweight
Jun-25-20	Initiated	Robert W. Baird	Outperform
Aug-12-19	Initiated	Citigroup	Buy
Aug-12-19	Initiated	Evercore ISI	Outperform
Aug-12-19	Initiated	Guggenheim	Buy
Aug-12-19	Initiated	ROTH Capital	Buy
Aug-12-19	Initiated	Raymond James	Outperform

View All

Mirum Pharmaceuticals Inc Stock (MIRM) Latest News

Jun 16, 2026

MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised) - TradingView

Jun 16, 2026

Jun 15, 2026

MIRM Maintained by Citizens -- Price Target Raised to $146 - GuruFocus

Jun 15, 2026

MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review - TradingView

Jun 15, 2026

H.C. Wainwright reiterates Mirum Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada

Jun 15, 2026

Citizens raises Mirum Pharmaceuticals stock price target on drug deal - Investing.com

Jun 15, 2026

Citizens raises Mirum Pharmaceuticals stock price target on drug deal By Investing.com - Investing.com Canada

Jun 15, 2026

Mirum and Incyte's zilurgisertib shows positive phase 2 data in FOP - MSN

Jun 15, 2026

Jun 14, 2026

Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva - lincolnjournal.com

Jun 14, 2026

Jun 11, 2026

Here's what key metrics tell us about Mirum Pharmaceuticals (MIRM) Q1 earnings - MSN

Jun 11, 2026

MIRM Maintains Overweight Rating -- Price Target Raised to $150 - GuruFocus

Jun 11, 2026

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Jun 11, 2026

Mirum Pharmaceuticals (NASDAQ:MIRM) Given New $150.00 Price Target at Morgan Stanley - MarketBeat

Jun 11, 2026

Jun 10, 2026

Why is Mirum Pharmaceuticals (MIRM) down 10.1% since last earnings report? - MSN

Jun 10, 2026

Jun 09, 2026

Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Sells 5,000 Shares of Stock - MarketBeat

Jun 09, 2026

Mirum Pharmaceuticals CFO Eric Bjerkholt sells $469k in shares - Investing.com UK

Jun 09, 2026

Mirum Pharmaceuticals CFO Eric Bjerkholt sells $469k in shares By Investing.com - Investing.com India

Jun 09, 2026

Mirum Pharmaceuticals (MIRM) CFO sells 5,000 shares after option exercise - Stock Titan

Jun 09, 2026

CenterBook Partners LP Purchases 37,010 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat

Jun 09, 2026